SecBot SecBot
Biotech Drug Report Generated Aug 3, 2026

Linzess

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved / marketed (Phase 3 completed for the pediatric ages 2–5 sNDA)
Time to market
Already marketed in the U.S. since FDA approval in 2012; the only pending item was the pediatric (ages 2–5) label-expansion sNDA decided around its May 24, 2026 PDUFA date.
Why 3/10
No next hard, dated catalyst is scheduled: the only pending binary, the FDA priority-review PDUFA of May 24, 2026 for the sNDA extending Linzess to functional constipation in children ages 2–5, has already passed, and the drug is a mature, approved, co-marketed product that is a small part of AbbVie's portfolio, so the defining binary is behind it.
Actionable Insight NEUTRAL

For ABBV holders, Linzess is immaterial to the thesis, treat it as steady, profitable co-marketed revenue, not a catalyst. Watch the 2026-08-06 IRWD Q2 earnings print (the co-commercialization partner) for Linzess U.S. net-sales momentum and any update on the ages 2–5 pediatric label decision from the May 2026 PDUFA, which the local data does not yet record as approved or rejected.

Price Chart

Loading chart...

Executive Summary

Linzess (linaclotide) is an FDA-approved (Aug 2012), mature oral treatment for chronic constipation disorders, co-marketed in the U.S. by AbbVie (the verified NYSE ticker tied to the drug in local data) and Ironwood Pharmaceuticals (IRWD), which reports the brand's U.S. net sales. The most recent hard catalyst, FDA priority review of a pediatric sNDA (ages 2–5 functional constipation) with a May 24, 2026 PDUFA, has passed, with the outcome unrecorded in local data; no new dated regulatory binary is visible in the next 12 months. Commercially, the brand is growing: IRWD reported Q1 2026 U.S. net sales of $272.5M (+97% y/y on improved net pricing) and 2026 guidance of $1.125–1.175B, though 2025 demand growth was a more modest ~11% and Ironwood's total 2025 revenue fell year over year.

How It Works

Linzess is a once-daily oral pill for chronic constipation conditions (irritable bowel syndrome with constipation and chronic idiopathic constipation, and the newer pediatric functional-constipation work). It works locally in the gut to trigger fluid secretion and faster bowel transit, a different, non-stimulant approach than laxatives. It was originally co-developed by Ironwood and (via Allergan's acquisition) is now co-marketed in the U.S. by AbbVie and Ironwood, with Ironwood reporting brand net sales in its filings.

Trial Status

FDA originally approved Linzess on 2012-08-30 (local FDA catalyst record). The label-expansion path is a completed AbbVie-sponsored Phase 3 study (NCT05652205, 123 enrolled, primary completion 2025-09-02) of linaclotide vs placebo in children ages 2–5 with functional constipation; FDA accepted the sNDA with priority review and set a PDUFA date of May 24, 2026, which has now passed with the outcome not yet recorded in local data.

The Two-Sided Case

▲ Bull Case4
Steady, profitable commercial asset: Q1 2026 LINZESS U.S. net sales hit $272.5M, up ~97% y/y on improved net pricing (IRWD 8-K/10-Q period report, local earnings analysis 2026-05-07).
AbbVie management (via IRWD) guided full-year 2026 LINZESS U.S. net sales of $1.125–1.175B with adj. EBITDA >$300M for Ironwood, a clear revenue floor for the brand.
Label-expansion optionality: FDA granted PRIORITY review to the pediatric ages 2–5 sNDA (PDUFA May 24, 2026) after a completed 123-patient AbbVie Phase 3 (NCT05652205); if approved, it extends the product's reach into a new patient population.
Demand still growing: LINZESS demand grew ~11% y/y in 2025 despite reimbursement pressure (IRWD FY2025 analysis, 2026-02-25).
▼ Bear Case4
No forward catalyst: the only scheduled regulatory binary (May 24, 2026 pediatric PDUFA) has passed and its outcome is unrecorded; for ABBV specifically, Linzess is a rounding error inside a mega-cap portfolio (~$250B market cap, $250.94/share at last quote).
For the co-partner IRWD, economics are pressured: total revenue fell from $351.4M (2024) to $296M (2025), a decline that the Q1 2026 net-pricing surge only partially offsets.
Mature GI market with multiple branded competitors and looming generic/biosimilar-style erosion typical of a drug first approved in 2012, patent life is finite and the model depends on continued net-pricing improvement.
PDUFA-day price data show no stock reaction captured for the pediatric decision (IRWD price flat at $3.92 around the May 24, 2026 date), consistent with the market treating it as low-stakes; outcome remains unconfirmed.

Upcoming Catalysts

  • IRWD Q2 2026 earnings (scheduled 2026-08-06), LINZESS U.S. net-sales trajectory and any pediatric label-update commentary
  • Confirmation/announcement of the FDA decision on the ages 2–5 functional-constipation sNDA (PDUFA May 24, 2026 passed; outcome not yet in local data)
  • Any future pediatric IBS-C label-expansion filing (no dated catalyst in local data)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov